Benchmark Maintains Speculative Buy on Genelux, Lowers Price Target to $20

Benzinga Newsdesk www.benzinga.com Negative 76.7%

Neg 76.7% Neu 0% Pos 0%

Benchmark analyst Bruce D. Jackson maintains Genelux (NASDAQ:GNLX) with a Speculative Buy and lowers the price target from $23 to $20.